Results 191 to 200 of about 131,135 (260)
Signaling Networks Regulating Metastatic Progression in Triple-Negative Breast Cancer. [PDF]
Senkowska Z +3 more
europepmc +1 more source
Pasta is a transcriptomic aging clock built on an age‐shift learning framework and trained on 17 000 samples across 21 datasets. It accurately predicts relative biological age across tissues, platforms, and species, captures stemness‐to‐senescence transitions, and identifies age‐modulatory perturbations.
Jérôme Salignon +6 more
wiley +1 more source
Targeting SIK2 with GRN-300 Potentiates Paclitaxel Efficacy in Triple-Negative Breast Cancer. [PDF]
Pina MA +6 more
europepmc +1 more source
Genetic ablation of Cep55 in Pten‐deficient mouse models delays tumorigenesis. Integrated multi‐omics analyses (proteomics, phosphoproteomics, and spatial transcriptomics) reveal that CEP55 regulates oncogenic signaling (RAS/ERK, PI3K/AKT), integrin/FAK‐mediated adhesion, extracellular matrix (ECM) remodeling, and endocytosis.
Behnam Rashidieh +22 more
wiley +1 more source
Lines Left Uncrossed: The Cost of Attrition in Metastatic Triple Negative Breast Cancer. [PDF]
Devi R N +3 more
europepmc +1 more source
Endothelin receptor type A (EDNRA) and the Hippo/YAP pathway form a self‐reinforcing loop that sustains triple‐negative breast cancer. EDNRA activates YAP through Gαq/11–Rho/ROCK–LATS signaling, while YAP/TEAD4 reciprocally drives EDNRA transcription.
Zehao Hong +10 more
wiley +1 more source
DUSP1: Triple-Negative Breast Cancer and Therapeutic Potential. [PDF]
Niture S +3 more
europepmc +1 more source
Metabolic adaption presents a vital survival strategy for E. multilocularis. This study identifies EmPDK as a central metabolic regulator governing glucose metabolic reprogramming. Oxidative stress activates EmHIF1α to induce EmPDK expression. Mechanistic characterization reveals this ROS/EmHIF1α/EmPDK axis drives glycolytic reprogramming to sustain ...
Huijuan Wang +5 more
wiley +1 more source
Immunotherapy Approaches for the Treatment of Triple-Negative Breast Cancer. [PDF]
Alharbi S +5 more
europepmc +1 more source
LA‐LYTAC repurposes the cancer‐enriched amino acid transporter LAT1 as a lysosomal trafficking receptor for targeted membrane‐protein degradation. A single phenylalanine‐derived ligand, modularly linked to antibodies or small‐molecule binders, recruits PD‐L1, EGFR, or integrins to LAT1, triggering transporter‐mediated internalization, lysosomal ...
Liquan Zhu +12 more
wiley +1 more source

